At Axol Bioscience, we support your pursuit of more effective, safer therapies. Like you, we believe that having more human-relevant disease models which will expand your scientific knowledge and de-risk drug development. We use human iPSCs to achieve this and have been doing this since 2006. We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models. We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well as cardiotoxicity to promote drug safety. When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier-stage modeling and safety testing and later-stage efficacy evaluation and improved patient selection. With these data comes better insights, helping you de-risk projects, reduce costs and save time during drug development. Over the last decade, development groups here at Axol have gained an international reputation for our production and characterization of ‘excitable’ cells. These include CiPA-validated cardiomyocytes, widely used in drug safety screening, and neural stem cells from patients with neurological conditions including Alzheimer’s disease and Parkinson’s disease, both primary areas for pharmaceutical development. We also generate astrocytes, microglia, and motor neurons. Axol Bioscience was founded in 2013 by Jonathan Milner and Yichen Shi. Since our merger with Censo Biotechnologies in 2021 we have evolved to offer custom in-house laboratory services to support biotech and pharma and a read-to-sequence library of cells and supporting media and reagents.